Organon OGN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Arcoxia | $59M-15.7% | $70M-1.4% | $71M+12.7% | $63M+1.6% | $62M+5.1% | |
| Atozet | $85M+26.9% | $67M-29.5% | $95M+10.5% | $86M+11.7% | $77M0.0% | |
| Brenzys | $20M-4.8% | $21M-8.7% | $23M+4.5% | $22M+57.1% | $14M0.0% | |
| Clarinex | $31M+3.3% | $30M+20.0% | $25M-26.5% | $34M0.0% | $34M+25.9% | |
| Cozaar/Hyzaar | $57M+7.5% | $53M-3.6% | $55M-1.8% | $56M+1.8% | $55M-3.5% | |
| Diprospan | $35M-7.9% | $38M-7.3% | $41M0.0% | $41M+36.7% | $30M-18.9% | |
| Dulera | $35M0.0% | $35M+2.9% | $34M-17.1% | $41M-4.7% | $43M-17.3% | |
| Emgality | $54M+10.2% | $49M-3.9% | $51M+21.4% | $42M+31.3% | $32M-15.8% | |
| Follistim AQ | $61M+5.2% | $58M-9.4% | $64M-13.5% | $74M+7.2% | $69M+4.5% | |
| Fosamax | $29M-19.4% | $36M-10.0% | $40M+17.6% | $34M+3.0% | $33M-15.4% | |
| Ganirelix Acetate Injection | $26M+8.3% | $24M+9.1% | $22M-18.5% | $27M0.0% | $27M0.0% | |
| Hadlima | $67M-2.9% | $69M+9.5% | $63M+26.0% | $50M+6.4% | $47M+6.8% | |
| Jada | $5M-75.0% | $20M0.0% | $20M+11.1% | $18M+20.0% | $15M-16.7% | |
| Marvelon/Mercilon | $26M+8.3% | $24M-22.6% | $31M-6.1% | $33M-15.4% | $39M+25.8% | |
| Nasonex | $65M0.0% | $65M+8.3% | $60M-9.1% | $66M-8.3% | $72M-5.3% | |
| Nexplanon/Implanon NXT | $201M-4.3% | $210M-5.8% | $223M-7.1% | $240M-3.2% | $248M-4.2% | |
| NuvaRing | $24M+50.0% | $16M-38.5% | $26M-7.1% | $28M+27.3% | $22M-12.0% | |
| Ontruzant | $5M-73.7% | $19M-38.7% | $31M0.0% | $31M+72.2% | $18M-47.1% | |
| Other Biosimilars | $24M+118% | $11M+22.2% | $9M+12.5% | $8M+60.0% | $5M-16.7% | |
| Other Cardiovascular | $28M0.0% | $28M-15.2% | $33M-2.9% | $34M+13.3% | $30M-11.8% | |
| Other Non-Opiod Pain, Bone and Dermatology | $68M-5.6% | $72M-10.0% | $80M0.0% | $80M+17.6% | $68M0.0% | |
| Other Respiratory | $12M0.0% | $12M0.0% | $12M-14.3% | $14M+7.7% | $13M-27.8% | |
| Other | $87M+2.4% | $85M-3.4% | $88M+1.1% | $87M+11.5% | $78M-10.3% | |
| Other | $18M+20.0% | $15M-28.6% | $21M-8.7% | $23M+4.5% | $22M-26.7% | |
| Other Women's Health | $46M0.0% | $46M+7.0% | $43M+2.4% | $42M-2.3% | $43M+10.3% | |
| Propecia | $30M+7.1% | $28M-15.2% | $33M+3.1% | $32M+23.1% | $26M-18.8% | |
| Proscar | $26M+8.3% | $24M-11.1% | $27M+22.7% | $22M-8.3% | $24M+9.1% | |
| Renflexis | $57M-6.6% | $61M-12.9% | $70M+11.1% | $63M+10.5% | $57M-10.9% | |
| Rosuzet | $6M-25.0% | $8M+33.3% | $6M0.0% | $6M+50.0% | $4M-69.2% | |
| Singulair | $40M-32.2% | $59M+11.3% | $53M-19.7% | $66M-10.8% | $74M-11.9% | |
| Vtama | $25M-35.9% | $39M+14.7% | $34M+9.7% | $31M+29.2% | $24M+100% | |
| Vytorin | $21M-16.0% | $25M0.0% | $25M-7.4% | $27M+17.4% | $23M-11.5% | |
| Zetia | $87M-3.3% | $90M-3.2% | $93M+25.7% | $74M-12.9% | $85M+10.4% | |
| Revenue by Geography | ||||||
| Asia Pacific and Japan | $226M-8.9% | $248M-1.2% | $251M+0.4% | $250M-0.4% | $251M+2.9% | |
| China | $194M-4.0% | $202M-7.8% | $219M+7.4% | $204M0.0% | $204M-4.2% | |
| Europe and Canada | $412M+1.5% | $406M-2.6% | $417M-0.5% | $419M+11.4% | $376M-10.5% | |
| Latin America, Middle East, Russia, and Africa | $247M-5.7% | $262M-8.4% | $286M+0.4% | $285M+18.8% | $240M-9.8% | |
| Other | $23M+35.3% | $17M-26.1% | $23M+4.5% | $22M-26.7% | $30M-9.1% | |
| U.S. | $358M-3.8% | $372M-8.4% | $406M-1.9% | $414M+0.5% | $412M-1.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Organon break its business down?
- Organon (OGN) reports revenue by product across 33 parts — Arcoxia, Atozet, Brenzys, Clarinex and Cozaar/Hyzaar. Each is extracted from the segment footnotes and tracked over time.
- Where does Organon's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Organon's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.